https://www.selleckchem.com/pr....oducts/3-3-cgamp.htm
Observational registries suggest ****-specific disparities persist in GDMT rates, and there may be key ****-specific differences in optimal dosing of GDMT in HFrEF patients. Underrepresentation of female patients in HF clinical trials is a key barrier, and **** disparities in HF clinical trial leadership may influence ****-specific knowledge generation of medical management of HFrEF patients. There are important ****-specific differences in GDMT use and response among female HFrEF patients that warrant further study. Increasing female repr
Мне нравится
Комментарий
Перепост
